



## LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference

January 5, 2011

BURLINGTON, N.C., Jan 05, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America<sup>(R)</sup> Holdings (LabCorp<sup>(R)</sup>) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 29<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp's presentation is planned for Wednesday, January 12, 2011 at 10:00 a.m. (PST).

A live audio webcast of the presentation will be available via the Company Web site at [www.labcorp.com](http://www.labcorp.com) and archived for replay.

### **About LabCorp<sup>(R)</sup>**

Laboratory Corporation of America<sup>(R)</sup> Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$4.7 billion in 2009, over 28,000 employees worldwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, DIANON Systems, Inc., US LABS, Monogram Biosciences, Inc. and Esoterix, Inc. and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trials testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: [www.labcorp.com](http://www.labcorp.com).

*This press release contains forward-looking statements. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2009, and subsequent SEC filings.*

SOURCE: Laboratory Corporation of America<sup>(R)</sup> Holdings

Laboratory Corporation of America Holdings

**Investor/Media Contact:**

Stephen Anderson, 336-436-5274

[www.labcorp.com](http://www.labcorp.com)